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Abstract
Estimating the causal effect of an exposure on an outcome is an important task in many eco-
nomical and biological studies. Mendelian randomization, in particular, uses genetic variants
as instruments to estimate causal effects in epidemiological studies. However, conventional
instrumental variable methods rely on some untestable assumptions, which may be violated
in real problems. In this paper, we adopt a Bayesian framework and build hierarchical mod-
els to incorporate invalid effects of instruments. We introduce an empirical Bayes estimator
for which some of the instruments are invalid by utilizing a Gaussian mixture prior. Theo-
retical performance and algorithm implementations are provided and illustrated. The reliable
performance of the proposed method is demonstrated in various simulation settings and on
real datasets concerning the causal effects of HDL cholesterol and LDL cholesterol on type 2
diabetes.
1 Introduction
Inferring the causality between exposures and outcomes is a crucial task in social science and epi-
demiology. Mendelian randomization (MR) uses genetic variants as instruments to measure the
causal effect of a specific exposure on an outcome (Lawlor et al., 2008; Davey Smith and Hemani,
2014). As a counterpart to the randomized controlled trial (RCT), MR can address areas where
an RCT would be impossible or unethical. With more and more available genome-wide associ-
ation studies (GWAS), researchers are able to find genetic variants which are robustly associated
with target exposures and infer the causality between exposures and outcomes via the variation of
genetic variants.
For instance, some recent studies raise an intriguing question whether there exists a causal
relationship between low-density lipoprotein (LDL) cholesterol and type 2 diabetes. Statin therapy
has been shown to reduce cardiovascular disease by lowering LDL (Baigent et al., 2005). However,
it is associated with a 9% increased risk for incident diabetes in RCT studies (Sattar et al., 2010). On
the other hand, another LDL lowering drug, Evolocumab, which uses a different bological pathway,
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has not been shown to have a significant effect on the incident diabetes in RCTs (Sabatine et al.,
2017). Thus, it is of interest to study whether the increased risk of diabetes is caused by lowering
LDL or as opposed to medication-specific effects. This problem is analyzed in this paper as a case
study with MR methods applied on summary data from GWAS.
There are many advantages of genetic variants serving as instruments. Firstly, in genetic asso-
ciations, the direction of causation is always from the genetic polymorphism to the phenotype of
interest, and not vice versa. Secondly, genetic variants are subject to relatively small measurement
error or confoundness, as opposed to conventionally measured environmental exposures, which are
often associated with a wide range of behavioral, social and physiological confounding factors.
Thirdly, MR is more cost-effective compared with RCTs.
On the other hand, some concerns are raised about applying the MR methods, such as weak
instruments, the confoundness of genotype, and canalization. Using multiple instruments can in-
crease the power of genotype-exposure and genotype-outcome association, but may also introduce
issues with linkage disequilibrium and pleiotropy (Davey Smith and Ebrahim, 2008; VanderWeele
et al., 2014).
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Figure 1: Illustrative diagram of conventional instrumental variable assumptions and the relaxed
assumptions in this paper. Crosses indicate violations of assumptions. Dashed arrows indicate the
effects allowed to exist in this paper. Parameters in the parentheses correspond to the notations of
such effects in model (1).
In conventional instrumental variable literature, the classical assumptions for valid instruments
(Figure 1) are (van Kippersluis and Rietveld, 2017)
(i) Relevance: The genetic variants Z have an effect on exposure D.
(ii) Independence: The genetic variantsZ are uncorrelated with any confounders of the exposure-
outcome relationship (U ).
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(iii) Exclusion restriction: The genetic variants Z affects outcome Y only through exposure D.
We say a genetic variant is valid if it satisfies assumptions (i)-(iii). However, not all of them are
fully realistic.
Assumption (i) can be fulfilled by selecting significant genetic variants from available GWAS,
while (ii) and (iii) are both untestable and may be violated in MR. For example, (iii) is known to
be problematic due to the pleiotropic effects of genetic variants, which means that one gene can
influence two or more seemingly unrelated phenotypic traits. Additionally, genetic variants may
have direct effects on the outcome.
The purpose of this paper is to develop a reliable estimator of the causal effect free of assumption
(iii). That is, corresponding to Figure 1, we allow the effects represented by the dashed arrow to
exist.
Many recent works study the relaxation of assumption (iii) from various perspectives. Bow-
den et al. (2015) introduced Egger’s regression method under the InSIDE assumption (instrument
strength independent of direct effect). Kang et al. (2016) develop a Lasso-type estimator under
some regularity conditions and the “partially invalid" assumption, which means some genetic vari-
ants are valid. Bowden et al. (2016) borrow tools from meta-analysis and develop a consistent
estimator when at least 50% of genetic variants are valid. A pleiotropy-robust MR method is in-
troduced by van Kippersluis and Rietveld (2017) using a subsample which is independent of the
exposure to estimate the pleiotropic effects. However, these types of assumptions can be hard to
check in reality and hence restrict the applicability of such estimators.
In a closely related article, Feller and Gelman (2015) consider a hierarchical model to account
for the randomness in data collection, unmeasured covariates, and treatment effect variation. How-
ever, their approach does not incorporate instrumental variables, while an MR problem is intrinsi-
cally equipped with genetic variants as instruments.
There are other recent advances on extending the applications of MR, such as estimation with
two-sample summary data (Bowden et al., 2017), the study of power and instrument strength re-
quirements (Pierce et al., 2010), and pathway identification (Burgess et al., 2015).
In this paper, we use the empirical Bayes hierarchical models to incorporate the pleiotropic
effects. Some noteworthy features of the proposed approach are:
(i) The proposed method does not rely on the “partially invalid" assumption or the InSIDE
assumption, which are required in the many existing literatures and may not be biological
plausible.
(ii) The proposed method is reliable even when there exist unbalanced pleiotropic effects and
partial invalidness.
(iii) The estimation procedure is based on an easily implemented and computationally efficient
algorithm, the Monte Carlo expectation-maximization (MCEM) algorithm.
The rest of this paper is organized as follows. In Section 2, we introduce notation, set up the
model, and motivate our estimators. In Section 3, we establish the theoretical guarantees of our
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estimators and illustrate the implementations of the estimation procedure. In Section 4, we show
how to apply our method with summary statistics. In Section 5, we apply our methods to both
simulated experiments and real studies. Finally, we conclude the paper with some remarks and
future research directions.
2 Model set-up
2.1 Notation
Observed genotypes are usually coded as the number of minor alleles, 0, 1, or 2. Without loss of
generality, we consider the case where the instruments are continuous in this paper. Let Zi ∈ RJ
denote the i-th observation of J instruments. Let Z ∈ Rn×J be an n × J matrix of genetic
variants whose i-th row consists of Zi. Let Zj ∈ Rn, j = 1, . . . , J denotes the j-th column of
Z. Let D = (D1, . . . , Dn)T ∈ Rn, where Di ∈ R is the i-th observation of the exposure. Let
Y = (Y1, . . . , Yn) ∈ Rn, where Yi ∈ R is the i-th observation of the outcome. Note that we
focus on quantitative type of exposures and outcomes in this paper. We assume that Y , D and each
column of Z are centered for the analysis.
For a vector r ∈ Rd, let ‖r‖1 =
∑d
i=1 |ri| and ‖r‖2 =
√∑d
i=1 r
2
i . For a matrix G ∈ Rm×d,
let PG be the m × m orthonormal projection matrix onto the column space of G, i.e. PG =
G(GTG)−1GT . Let P⊥G = Im×m − PG. For a square matrix G′ ∈ Rd×d, let Λmax(G′) be the
largest eigenvalue ofG′ and Λmin(G′) be the smallest eigenvalue ofG′. LetG′′ ∈ Rd×d be another
square matrix. We say G′  G′′ iff G′′ −G′ is a positive definite matrix.
For a random variable V ∈ R, let Var(V ) denote the variance of V such that Var(V ) = E[(V −
E[V ])2]. LetN(µ, σ2) denote the Gaussian distribution with mean µ and variance σ2. Let Ψ(·) and
φ(·) be the cdf and pdf of a standard Gaussian random variable, respectively. Let U[a, b] denote the
uniform distribution on [a, b] for a < b.
2.2 Model specification
Suppose that we observe i.i.d. copies of (Zi, Di, Yi), i = 1, . . . , n. We adopt the Neyman-Rubin’s
potential outcome framework (Rubin, 1974; Splawa-Neyman, 1990) and set up the model for ob-
served data under assumptions (i) and (ii).
With some basic derivations of the potential outcome model, we consider the following the
model for observed data. For i = 1, . . . , n,{
Di = Ziγ + vi
Yi = βDi + Ziα+ i,
(1)
where (vi, i) has mean zero and covariance matrix
(
σ2v σ
2
v
σ2v σ
2

)
conditioning on Z, β ∈ R is the
causal effect of interest, γ = (γ1, . . . , γJ)T ∈ RJ with γj the strength of the j-th instrumental
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variable, and α = (α1, . . . , αJ)T ∈ RJ with αj the total effect of j-th genetic variant Zj on the
outcome Y not via the exposureD or the common confounders U . For simplicity, we refer to αj as
the pleiotropic effect of Zj . Moreover, the effect of the common confounders U in Figure 1 enters
the model via σ2v.
When σ2v is non-zero, D is correlated with the error term  in the exposure-outcome model.
Therefore, the second equation in model (1) does not satisfy the classical linear model assumptions.
This issue can be taken care of by a well-established instrumental variable method, the Two-Stage
Least Square (TSLS) estimation, provided that all of the genetic variants are valid, i.e. α = 0.
Specifically, one can construct a proxy of D, namely the least square estimate Dˆ, such that
Dˆ = Zγˆ, (2)
where γˆ = (ZTZ)−1ZTD.
To ease the notation, let vˆi = Di− Dˆi and ηˆi = i +βvˆi. We can rewrite the exposure-outcome
model as
Yi = βDˆi + Ziα+ ηˆi. (3)
Note that E[ZTi ηˆi] = 0 by the our assumption and construction. Thus, if α = 0, model (3) satisfies
the moment condition E[ZT (Y − βDˆ)] = 0, which sheds light on the TSLS estimator. Formally,
define the TSLS estimator of β as
βˆ(tsls) = argmin
β∈R
‖Y − Dˆβ‖22.
It is easy to see that βˆ(tsls) is an asymptotically unbiased estimator of β assuming that α = 0 and
‖Dˆ‖22/n→ K1 > 0 as n→∞.
Withα unknown and possibly nonzero, one may consider the multivariate least square estimator,
say (βˇ(tsls), αˇ(tsls)), such that
(βˇ(tsls), αˇ(tsls)) = argmin
(β,α)∈RJ+1
‖Y − Dˆβ − Zα‖22. (4)
However, it can be seen from (2) that Dˆ is a linear combination of Z and hence the column space
of matrix (Dˆ, Z) ∈ Rn×(J+1) is rank deficient. As a result, the parameter of interest, β, cannot be
not identified.
In this paper, we consider a variation of (4), which can be formulated as the regularized regres-
sion approach, i.e.
(β˜(2sls), α˜(2sls)) = argmin
(β,α)∈RJ+1
‖Y − Dˆβ − Zα‖22 +Rλ(α), (5)
where Rλ(a) is a regularization term indexed with λ.
The regularized estimators resulted from (5) are equivalent to the posterior mode under a nonin-
formative prior of β and pi(α|λ) of α, where Rλ(a) = − log pi(α|λ) (Rocˇková and George, 2016).
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In addition, the square loss function in (5) corresponds to the negative logarithm of the standard
Gaussian density for ηˆi.
Inspired by this equivalence and in order to adapt to general assumptions on α, we adopt the
Bayesian framework and manipulate the regularization term by specifying some flexible hierarchi-
cal priors on α.
3 Handling nuisance parameters: hierarchical models
The hierarchical model is an effective tool for pooling information and simultaneous inference. A
large class of shrinkage estimators are generated within this framework, such as the James-Stein
estimator (James and Stein, 1961) and the SURE estimator (Xie et al., 2012). The risk properties of
shrinkage estimators have been well-studied through a series of papers (Baranchik, 1970; Brown,
1971; Brandwein and Strawderman, 1991).
3.1 Gaussian prior with a data-driven location
Effect sizes in genetics are often modeled under a Gaussian prior (Stephens and Balding, 2009).
When specifying the location parameter, we need to take into consideration the unbalanced pleiotropic
effects, where the mean of the α is not zero. We specify the prior distribution of α as
α|µα, τ2 ∼ N(µα, τ2IJ×J), (6)
where µα is unknown and τ2 is assumed to be known for the purpose of illustration.
3.1.1 Theoretical guarantees
We treat ηˆi as a Gaussian random variable with mean zero and variance σ2η to keep the form of
square loss in the target function of (5). Assume that τ2 and σ2η are known for the purpose of
illustration.
For some given µα, τ2, and σ2η , let (βˆ
µα , αˆµα) be the posterior mode under the prior (6). We
can obtain that
(βˆµα , αˆµα) = argmin
(β,α)∈R(J+1)
‖Y − Dˆβ − Zα‖22 +
σ2η
τ2
‖α− µα‖22. (7)
Define two matrices A and B, such that
A =
1
nσ2η
ZTPDˆZ and B =
1
n
(
ZTZ
σ2η
+ τ−2IJ×J).
Assumption 3.1. Let c∗ be the largest eigenvalue of AB−1 satisfying 0 < c∗ < 1.
Next theorem provides an empirical error bound for βˆµα defined in (7).
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Theorem 3.2. Suppose that Assumption 3.1 holds. For some given µα, τ2, and σ2η , the absolute
error of βˆµα defined in (7) satisfies
|βˆµα − β| ≤ c
∗σ2η‖γˆ‖2‖α− µα‖2
τ2(1− c∗)DˆT Dˆ +
c∗‖γˆ‖2‖ZTP⊥Dˆ ηˆ‖2
(1− c∗)DˆT Dˆ +
|DˆT ηˆ|
DˆT Dˆ
. (8)
Now we provide the conditions for c∗ to fall in the (0, 1) interval.
Lemma 3.3. If 0 < τ2 < ∞, 0 < σ2η < ∞, ‖Dˆ‖2 > 0, and Λmin(ZTZ/n) > 0, Assumption 3.1
is satisfied.
It is not hard to see that for finite αj − µα and γˆj , j = 1, . . . , J , the right-hand side of (8) is of
order J/n under the assumptions of Lemma 3.3. Thus, βˆµα is asymptotically unbiased for J  n
under our assumptions.
Another important constant appears in the error bound is c∗, which can be viewed as a regularity
constant on D and Z. It can be seen that the error bound could become very large when c∗ is very
close to 1. Thus, it is necessary to evaluate c∗, which in fact can be easily calculated given τ2, σ2η ,
and the observations. It is simpler and calculable compared to the restricted isometry property (RIP)
constants, which are used to bound the Lasso-type estimator in (Kang et al., 2016). Moreover, this
estimator does not depend on the number of valid instruments or the InSIDE assumption, which
are always untestable in real applications.
Moreover, the performance of βˆµα can be understood from the regularization perspective. From
the formulation of (7) one can see that (βˆµα , αˆµα) is a ridge-type regression estimator with penalty
factor σ2η/τ
2 and a drift term µα. It is well known that ridge-type penalty has variance stabilization
effect in the scenario of collinearity and shrinkage effect towards 0. By adding a ridge-type regu-
larization term, we manipulate the variance-bias trade-off and achieve an asymptotically unbiased
estimator under mild conditions. One should also notice that only the nuisance parameters α are
penalized, not the parameter of interest β, which excludes the bias directly caused by regulariza-
tion. Finally, the drift term µα as well as the penalty term σ2η/τ
2 are always unknown and need to
be estimated.
Now we formally set up the hierarchical structure for the observed data and involved parameters.
3.1.2 The empirical Bayes hierarchical model
For the unobserved variance components τ2 and σ2η , a common choice is to place inverse-gamma
priors on them. As one can see from (7), τ2 and σ2η together play a role in tuning the penalty
parameter σ2η/τ
2 and hence have an effect on the accuracy of the estimation but do not change the
form of the estimator. Thus, the result of Theorem 3.2 can still be applied with estimated σ2η and
τ2.
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As illustrated in Figure 2, the fully Bayesian specification of the model is
Y |Dˆ, Z, β, α, σ2η ∼ N(Dˆβ + Zα, σ2ηIn×n) (9)
α|µα, τ2 ∼ N(µα, τ2IJ×J) (10)
τ−2|ν1, ν2 ∼ Gamma(ν1, ν2) (11)
σ−2η |ν3, ν4 ∼ Gamma(ν3, ν4), (12)
where β and µα are unknown, Gamma(a, b) is Gamma distribution with shape parameter a and
rate parameter b, and ν1 − ν4 are some prespecified constants based on our prior knowledge. In
order to make the priors noninfluential, we set ν1 − ν4 to be small constants during the estimation.
This hierarchical structure gives the marginal prior of α as
αj |µα, ν1, ν2 ∼iid T2ν1(µα, ν2/ν1), j = 1, . . . , J,
where Tk(µ, σ2) is a Student’s t-distribution with mean µ, variance σ2, and degree of freedom 2ν1.
Data
α β σ−2η
µα τ−2
ν1, ν2
ν3, ν4
Figure 2: The hierarchical structure of parameters for the hierarchical model (9)-(12). All “squares"
represent parameters in the marginal distribution and all “circles" represent represent parameters
which only appear in the “complete-data" posterior.
For parameters β and µα, we adopt the empirical Bayes framework and estimate them with
the marginal maximum likelihood estimators. The empirical Bayes approach can be viewed as an
approximation of a fully hierarchical Bayes analysis (Carlin and Gelfand, 1990, 1991). It allows a
second-level model learning and has been widely used for combining information and multi-task
learning in statistics and machine learning (Efron, 1996; Ten Have and Localio, 1999; Bakker and
Heskes, 2003). This empirical Bayes set-up allows the estimates of α to share information and
borrow strength from each coordinate (Muralidharan, 2010).
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3.1.3 The MCEM algorithm
We briefly explain the algorithm implementations in this section. Details can be found in the
Appendix. We adopt a variation of expectation-maximization (EM) algorithm, the Monte Carlo
EM (MCEM) algorithm, to achieve the estimation (Meng and Schilling, 1996; Levine and Casella,
2001; Chen et al., 2002). The EM algorithm is a widely-adopted and computationally fast algorithm
for handling missing values and unobserved variables. When the expectation in the “E-step" does
not have a closed form, one can approximate it with Monte Carlo samples. The MCEM algorithm
iteratively estimates the marginal parameters and samples the middle-layered parameters until it
converges. (See (Casella, 2001) for a general description.)
Let D denote the observed data (Zi, Di, Yi) for i = 1, . . . , n. The optimization starts with
some initial value (βˆ(0), µˆ(0)α ). At t-th iteration (t = 1, 2, . . . ), generate (α
(t)
i , (τ
2)
(t)
i , (σ
2
η)
(t)
i ), i =
1, . . . ,m, from the posterior distribution of (α, τ2, σ2η) under the current estimate (βˆ
(t−1), µˆ(t−1)α ).
Then calculate the Monte Carlo estimate of Eα,τ2,σ2η [log p(β, µα|D, α, τ2, σ2η)], which is
1
m
m∑
i=1
log p(β, µα|D, α(t)i , (τ2)(t)i , (σ2η)(t)i ). (13)
At the M-step, we compute the maximizer of (13), i.e.
(βˆ(t), µˆ(t)α ) = argmax
(β,µα)∈R2
1
m
m∑
i=1
log p(β, µα|D, α(t)i , (τ2)(t)i , (σ2η)(t)i ).
At the convergence of (βˆ(t), µˆ(t)α ), produce βˆ(t) as the final estimate of β.
3.2 A mixture Gaussian prior
If, in fact, some genetic variants are valid instruments, i.e. αj = 0 for some j ∈ {1, . . . , J}, a
single Gaussian prior may not be the appropriate structure to put on α. A prior distribution which
can induce a sparse posterior mode is preferable.
In the Bayesian framework, the “Spike-and-Slab" prior (George and McCulloch, 1993) is a
well-established Bayesian variable selection procedure via a sequence of papers (George and Mc-
Culloch, 1993, 1997; Rocˇková and George, 2014, 2016). It consists of a spike component and a
slab component both centered at 0. This prior imposes larger shrinkage effects on the relatively
small estimates and smaller shrinkage effects on the relatively large estimates.
Our goal here is estimation rather than variable selection and our strategy is to add a spike
component to a Gaussian component with an unknown center. More specifically, we consider a
mixture Gaussian prior as
αj |µα, ξj , τ2, ν0 ∼ind N(ξjµα, ν0τ2 + (1− ν0)ξjτ2) (14)
ξj |p0 ∼iid Ber(p0), (15)
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where µα and τ2 are unknown parameters, ν0 is a very small constant, and Ber(p0) is a Bernoulli
distribution generating 1 with probability p0.
If ξj = 1, the prior distribution of αj is N(µα, τ2); if ξj = 0, the prior distribution of αj is
N(0, ν0τ
2) with a small constant ν0 (say 0.001 as in the simulation). The parameter p0 can be
interpreted as the overall level of sparsity.
The priors in (14) and (15) allow a data-driven location of the “slab" component as well as
a data-driven sparseness parameter. In the same spirit as a single Gaussian prior, the purpose
of fitting the mean of the nonzero component is to deal with unbalanced pleiotropic effects and
reduce the estimation error. The purpose of a data-dependent p0 is to allow the determination of
the unknown sparsity. This formulation is able to incorporate the sparse structure of α and deal
with the unbalanced pleiotropic effects at the same time (see Figure 3 for an example).
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Figure 3: Density plot of 10000 realizations of αj from the mixture distribution (14)-(15) with
p0 = 0.8, τ2 = 0.01, ν0 = 0.001, µα = −0.2, 0, and 0.2 from left to right.
Given µα, ξ, τ2, and σ2η , the posterior mode under prior (14) can be written as
(βˆ(µα,ξ), αˆ(µα,ξ)) = argmin
(β,α)∈RJ+1
‖Y − Dˆβ − Zα‖22 +
σ2η
τ2
J∑
j=1
(αj − µαξj)2
ν0 + (1− ν0)ξj . (16)
From the regularization perspective, (16) implies that each αj with ξj = 0 is shrunk towards 0 with
penalty level σ2η/(ν0τ
2) and each αj with ξj = 1 is shrunk towards µα with penalty level σ2η/τ
2.
Let Γξ be a diagonal matrix with (Γξ)j,j = (ν0 + (1 − ν0)ξj)τ2 for j = 1, . . . J and Bξ =
(ZTZ/σ2η + Γ
−1
ξ )/n. We require the following assumption to hold.
Assumption 3.4. Let c∗∗ be the largest eigenvalue of AB−1ξ such that 0 < c
∗∗ < 1.
Corollary 3.5. Suppose that Assumption 3.4 holds. For given µα, ξ, τ2, and σ2η , the estimation
error of βˆ(µα,ξ) defined in (16) satisfies
|βˆ(µα,ξ) − β| ≤c
∗∗σ2η‖γˆ‖2‖Γ−1ξ (α− µαξ)‖2
(1− c∗∗)DˆT Dˆ +
c∗∗‖γˆ‖2‖ZTP⊥Dˆ ηˆ‖2
(1− c∗∗)DˆT Dˆ +
|DˆT ηˆ|
DˆT Dˆ
. (17)
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Now we compare the error bound of mixture Gaussian prior in (17) with that of single Gaussian
prior in (8). From the definition of Γξ, one can see that see that Γξ  Γ with the same τ2. By some
simple linear algebra derivation, one can show that c∗∗ ≤ c∗, which is preferred. On the other hand,
if valid instruments are all correctly selected, that is, if ξj = 0 for αj = 0 (j = 1, . . . , J),
|Γ−1ξ (α− µαξ)‖22 =
∑
j:ξj=1
1
τ2
(α− µα)2 ≤ ‖Γ−1(α− µα)‖22.
Thus, the mixture prior can possibly improve the estimation accuracy for sparse α, but also depends
on the estimation of ξ and µα.
For the estimation side, we again use (11) and (12) as priors for unknown variance components
τ2 and σ2η and build a fully Bayesian hierarchical model together with (14) and (15). We call such
estimator of causal effect the Empirical Bayes estimator for MR, or the MR-EB estimator.
The hierarchical structure of the parameters is given in Figure 4. The estimation procedure is
again via the MCEM algorithm. Implementation details are provided in the Appendix.
Data
α β σ−2η
µα τ−2 ξ
p0ν1, ν2
ν3, ν4
Figure 4: The hierarchical structure of parameters under the priors (11), (12), (14), and (15). All
“squares" represent parameters in the marginal distribution and all “circles" represent parameters
which only appear in the “complete-data" posterior.
4 Implementation with summary data
Many public GWAS datasets are available only up to summary statistics for the association studies
between individual genetic variants and traits. Moreover, in many cases the data on the interested
exposure and that on the interested outcome are available in independent samples. Developing valid
methodology for this type of data can broaden the applicability of MR and is of great relevance.
Specifically, for j = 1, . . . , J , let Ω˜j ∈ R be the association estimate between the interested
outcome Y and the j-th genetic variant Zj , σ˜2Ω,j ∈ R be the estimated variance of Ω˜j , and γ˜j ∈ R
be the association estimate between the interested exposure D and Zj . Let γ˜(2) be a version of γ˜
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obtained from an independent sample (Z(2), D(2)). We generalize our methods to the case where
only (γ˜(2), Ω˜, σ˜2Ω) are available under some conditions.
Regarding our notation,
γ˜j =
ZTj D
ZTj Zj
and Ω˜j =
ZTj Y
ZTj Zj
, j = 1, . . . J.
Assuming that ZTZ is a diagonal matrix, it is easy to see that Dˆ = PZD = Zγ˜, PZY = ZΩ˜,
and Var(Ω˜j) = σ2η/(Z
T
j Zj). Thus, the sample moments used throughout the computation can be
equivalently represented by the summary statistics, i.e.
ZTZ/σ2η = Σ
−1
Ω (18)
ZT Dˆ/σ2η = Σ
−1
Ω γ˜ (19)
ZTY/σ2η = Σ
−1
Ω Ωˆ (20)
DˆT Dˆ/σ2η = γ˜
TΣ−1Ω γ˜ (21)
DˆTY/σ2η = γ˜
TΣ−1Ω Ω˜, (22)
where ΣΩ is a diagonal matrix with (ΣΩ)j,j = Var(Ω˜j). In our estimation procedure, the un-
observed quantities appeared on the left-hand sides of (18) - (22) are replaced by the observed
versions of the right-hand sides of (18) - (22), where γ˜ is replaced by γ˜(2) and ΣΩ is replaced by
a diagonal matrix with the j-th diagonal element equal to σˆ2Ω,j . Since the term σ
2
η is absorbed into
the observed statistics already, it is unnecessary to be updated through the estimation. Thus, we are
able to get an MR-EB estimator with summary statistics based on the hierarchical priors (11), (14),
and (15) as in Section 3.1 and 3.2.
5 Simulations and real studies
5.1 Synthetic data experiments
We evaluate the performance of the proposed methods in comparison to the TSLS and the Lasso
estimators in various simulation settings. In particular, we focus on the behavior of MR-EB estima-
tor which is most general and can explore the possibly sparse structure of α. The TSLS estimator
is computed as a benchmark from classical instrumental variable literatures. The Lasso estimator,
which is essentially the sisVIVE estimator in (Kang et al., 2016), is proposed to deal with sparse α
and hence is added in comparison. The threshold parameter is chosen by 10-fold cross validation
as suggested in the paper.
In all the experiments presented in this section, each sample consists of n = 1000 observations
and J = 30 candidate genetic variants. The genetic variants Zi, i = 1, . . . , n, are drawn from a
multivariate normal distribution with mean zero and identity covariance matrix. The phenotypes
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(Di, Yi), i = 1, . . . , n, are generated according to model (1), where each (vi, i) is generated from
a bivariate normal distribution with mean zero and covariance matrix
(
1 0.2
0.2 1
)
.
With and without the InSIDE assumption, we allow the following parameters to vary: the
strength of causal effect, the distribution of pleiotropic effects and the proportion of invalid in-
struments. Specifically, we consider two levels of signal strength β ∈ {0, 0.2}, three levels of the
mean of pleiotropic effects µα ∈ {−0.2, 0, 0.2}, and eleven levels of sparsity p0 ∈ {0, 0.1, . . . , 1}.
In each of these settings, we generate γj from U[0.1, 0.3], ξj from Ber(1, p0), and uj from U[µα −
0.2, µα+ 0.2] in an i.i.d. fashion for j = 1, . . . , J . The pleiotropic effects αj = ξjuj if the InSIDE
assumption is satisfied and αj = (0.2γj + uj)ξj if the InSIDE assumption is not satisfied, for
j = 1, . . . , J . In each setting, the experiment is independently replicated for 100 times and the
mean square error (MSE) is reported.
As explained before, we take ν0 − ν4 to be small numbers. Specifically, we set ν0 = 0.001,
ν1 = 2, ν2 = 0.4 and ν3 = ν4 = 0.0001. For the initial values, take βˆ(0) = µˆ
(0)
α = 0 and
pˆ
(0)
0 = 0.5.
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Figure 5: β = 0 and InSIDE assumption is satisfied. The x-axis is the true sparsity level p0
for all the plots. For the left three plots, each point represents the MSE of 100 experiments for
µα = −0.2, 0, and 0.2 from left to right, respectively. In the rightmost plot, each point represents
the realized c∗∗ for the MR-EB estimator in the experiments presented in the left three plots.
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Figure 6: β = 0.2 and InSIDE assumption is satisfied. The x-axis is the true sparsity level p0
for all the plots. For the left three plots, each point represents the MSE of 100 experiments for
µα = −0.2, 0, and 0.2 from left to right, respectively. In the rightmost plot, each point represents
the realized c∗∗ for the MR-EB estimator in the experiments presented in the left three plots.
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
Methods 2SLS LASSO MR−EB
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
µα −0.2 0 0.2
Figure 7: β = 0 and InSIDE assumption is not satisfied. The x-axis is the true sparsity level p0
for all the plots. For the left three plots, each point represents the MSE of 100 experiments for
µα = −0.2, 0, and 0.2 from left to right, respectively. In the rightmost plot, each point represents
the realized c∗∗ for the MR-EB estimator in the experiments presented in the left three plots.
14
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
Methods 2SLS LASSO MR−EB
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
µα −0.2 0 0.2
Figure 8: β = 0.2 and InSIDE assumption is not satisfied. The x-axis is the true sparsity level
p0 for all the plots. For the left three plots, each point represents the MSE of 100 experiments for
µα = −0.2, 0, and 0.2 from left to right, respectively. In the rightmost plot, each point represents
the realized c∗∗ for the MR-EB estimator in the experiments presented in the left three plots.
From the left three plots in each row, one can see that the MR-EB estimator remains stable
in the presence of unbalanced pleiotropic effects, while the other two approaches result in much
larger estimation errors. In the balanced pleiotropic effect scenario, the performances of all three
methods are comparable.
Moreover, the number of nonzero pleiotropic effects also plays an important role in the es-
timation accuracy. One can see that the MR-EB estimator has remarkably reliable performance
under different levels of sparseness, even when all the genetic variants are invalid. Though it has
relatively large errors when more than 80% of genetic variants are invalid, it is still much more
accurate than its counterparts. When the proportion of invalid instruments is less than 50%, the
proposed estimator is no worse than the Lasso estimator, which shows its stability and adaptivity
to the sparsity. On the other hand, when the proportion of invalid instruments is greater than 50%,
the Lasso estimator has similar performance as the TSLS estimator and both estimators have large
estimation errors.
Furthermore, the MR-EB estimator has MSE close to zero no matter whether the InSIDE as-
sumption is satisfied or not. In comparison, the MSE of the TSLS estimator and the Lasso estimator
change significantly when InSIDE assumption does not hold and the pleiotropic effects are unbal-
anced.
The plots of realized c∗∗ are to facilitate understanding the performance of the MR-EB estima-
tor. One can see that as the number of nonzero pleiotropic effects increases, c∗∗ increases towards
1 superlinearly and it becomes close to 1 when more than 80% of genetic variants are invalid.
5.2 Case study (i): HDL and type 2 diabetes
The high density lipoprotein (HDL) cholesterol has the reputation as a "good" cholesterol, since
it is negatively associated in observational studies with the risk of many diseases, for example,
myocardial infarction and type 2 diabetes. However, the supporting studies have been unable to
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control various potential confounders, while the negative association with HDL has lacked con-
vincing biological mechanisms. Hence, the association does not necessarily imply a causal effect.
Haase et al. (2012) use the traditional MR method to estimate the causality between HDL and
the risk of type 2 diabetes. Their results suggest that there is no causal effect of HDL on type 2
diabetes. We access a different set of summary data from MRbase (Hemani et al., 2016) and arrive
at a similar conclusion for a related trait. The MRbase is a database and an analytical platform
for MR studies, which provides summary data of many published GWAS and some basic analytic
tools.
The exposure data is measured plasma HDL cholesterol (unit: mg/dL) from the Global Lipids
Genetics Consortium (Willer et al., 2013) with a sample size 187167. The outcome data is mea-
sured fasting glucose (unit: mmol/L) from the Meta-Analyses of Glucose and Insulin-related traits
Consortium (Dupuis et al., 2010) with a sample size 46186. Hyperglycemia in the fasting state is
one of the criteria that defines type 2 diabetes (Kahn, 2003). Thus, fasting glucose is an important
indicator of Type 2 diabetes.
For the analysis, 83 genetic variants are selected and harmonized automatically by the MRbase,
which excludes linkage disequilibrium and selects variants which are robustly associated with the
target traits with the genome-wide significance threshold 5× 10−8.
Four method are applied on this dataset. The estimate given by TSLS is -0.0282 mmol/L per
mg/dL; the estimate given by the Egger’s regression (Bowden et al., 2015) is -0.0345 mmol/L per
mg/dL; the estimate given by the inverse-variance weighted median estimator (Bowden et al., 2016)
is -0.0290 mmol/L per mg/dL; the estimate given by the MR-EB estimator is -0.0312 mmol/L per
mg/dL, where the hyper-parameters ν0 − ν2 are specified as 0.001, 2, and 0.2, respectively. One
can see that these methods generate similar estimates for this dataset.
5.3 Case study (ii): LDL and type 2 diabetes
As introduced at the beginning of the paper, we study the causal effect of LDL cholesterol on the
type 2 diabetes in this section.
The exposure data is measured plasma LDL cholesterol (unit: mg/dL) from the Global Lipids
Genetics Consortium (Willer et al., 2013) with a sample size 173082. The outcome data is the
fasting glucose (unit: mmol/dL) which is from the same source of data as in case study (i). For the
analysis, 72 genetic variants are selected and harmonized.
For this dataset, the estimate given by TSLS is -0.0157 mmol/L per mg/dL; the estimate given
by the Egger’s regression (Bowden et al., 2015) is -0.0248 mmol/L per mg/dL; the estimate given
by the inverse-variance weighted median estimator (Bowden et al., 2016) is -0.0121 mmol/L per
mg/dL; the estimate given by the MR-EB estimator is -0.0038 mmol/L per mg/dL, for which the
hyper-parameters ν0 − ν2 are specified as 0.001, 2, and 0.2, respectively.
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6 Discussion
In this paper, we have developed empirical Bayes hierarchical models for estimating the causal ef-
fect in the presence of invalid instruments for MR studies. Due to the confoundness of pleiotropic
effects, the causal effect cannot be identified with the traditional TSLS estimator. Instead of mak-
ing structural assumptions about the unobserved pleiotropic effects (such as the “partially invalid"
assumption and the InSIDE assumption), we set up hierarchical models, which utilize the regular-
ization structure to share information across the hierarchy. Empirical Bayes approaches are em-
ployed to estimate the unknown marginal parameters, which take care of the unbalanced pleiotropic
effects and the unknown sparsity. Theoretically, we have developed empirical error bounds which
shed light on a class of shrinkage estimators. The resulting MR-EB estimator can be efficiently
implemented with the MCEM algorithm.
The simulation results demonstrate the reliable and compelling performance of the MR-EB esti-
mator throughout different levels of signal strength and sparsity, in comparison to existing methods.
The proposed method remains reliable in the presence of unbalance pleiotropic effects and when
the InSIDE assumption is not satisfied. The simulation results are consistent with the theorems and
discussions presented in the previous section.
There are still interesting and open problems in the scope of current topic. Firstly, many epi-
demiological studies are interested in the causal effect of exposures on the risk of certain diseases.
Thus, it is an important task to provide a reliable procedure to estimate the causal effect for the
binary outcome data, or equivalently the probability of occurrence of an event. Under some model
assumptions, one can generalize the proposed approach to the logistic and probit models. Secondly,
this paper together with many previous works have been focusing on the estimation procedure,
while generating valid interval estimates with mild conditions and cheap computation remains to
be a challenging and worthwhile topic. Thirdly, to further reduce the assumptions on the prior
distribution, one may also consider fitting a nonparametric empirical Bayes model.
The R code of the implementation of the proposed methods is available from the author upon
request.
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Appendix
A Proof of theorems and lemmas
A.1 Proof of Theorem 3.2
Proof. Define Γ = τ2IJ×J and Ξ =
(
DˆT Dˆ/σ2η Dˆ
TZ/σ2η
ZT Dˆ/σ2η Z
TZ/σ2η + Γ
−1
)−1
. From (7), we can get
(
βˆµα
αˆµα
)
= Ξ
(
DˆTY/σ2η
ZˆTY/σ2η + Γ
−1µα
)
= Ξ
(
DˆTY/σ2η
ZTY/σ2η + Γ
−1α+ Γ−1(µα − α)
)
=
(
β
α
)
+ Ξ
(
DˆT ηˆ/σ2η
ZT ηˆ/σ2η + Γ
−1(µα − α)
)
.
From the above derivation, we can obtain that
βˆµα = β + Ξ1,1Dˆ
T ηˆ/σ2η + Ξ1,J(Z
T ηˆ/σ2η + Γ
−1 (µα − α))
= β + Ξ1,1Dˆ
T ηˆ/σ2η + Ξ1,JZ
TPDˆηˆ/σ
2
η︸ ︷︷ ︸
E1
+ Ξ1,J(Z
TP⊥
Dˆ
ηˆ/σ2η + Γ
−1 (µα − α))︸ ︷︷ ︸
E2
. (23)
By the matrix inverse formula and some simple algebra, we can get
ΞJ,J =
(
ZTZ/σ2η + Γ
−1 − Z
T DˆDˆTZ/σ2η
DˆT Dˆ
)−1
= (B −A)−1 (24)
Ξ1,J = −Dˆ
TZΞJ,J
DˆT Dˆ
= −σ
2
η γˆ
TA(B −A)−1
DˆT Dˆ
, (25)
where the last step is due to DˆTZ = DˆTPDˆZ = γˆ
TZTPDˆZ and (24).
Thus, for E1 in (23), we have
E1 = Ξ1,1Dˆ
T ηˆ/σ2η +
Ξ1,JZ
T DˆDˆT ηˆ/σ2η
DˆT Dˆ
=
(
Ξ1,1 − Ξ1,JΞ−1J,JΞJ,1
)
DˆT ηˆ/σ2η
=
DˆT ηˆ
DˆT Dˆ
, (26)
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where the second equality can be seen from the first part of (25) and the third equality is again by
the matrix inverse formula.
|E2| =
∣∣∣∣∣−σ
2
η γˆ
TA(B −A)−1(ZTP⊥
Dˆ
ηˆ/σ2η + Γ
−1 (µα − α))
DˆT Dˆ
∣∣∣∣∣
≤
Λmax(A(B −A)−1)
(
σ2η‖γˆ‖2‖Γ−1(α− µα)‖2 + ‖γˆ‖2‖ZTP⊥Dˆ ηˆ‖2
)
DˆT Dˆ
≤ σ
2
ηc
∗‖γˆ‖2‖Γ−1(α− µα)‖2
(1− c∗)DˆT Dˆ +
c∗‖γˆ‖2‖ZTP⊥Dˆ ηˆ‖2
(1− c∗)DˆT Dˆ
=
σ2ηc
∗‖γˆ‖2‖α− µα‖2
τ2(1− c∗)DˆT Dˆ +
c∗‖γˆ‖2‖ZTP⊥Dˆ ηˆ‖2
(1− c∗)DˆT Dˆ , (27)
where the last inequality is due to A(B − A)−1 = AB−1(I − AB−1)−1, Λmax(AB−1(I −
AB−1)−1) ≤ c∗1−c∗ <∞, and 0 < c∗ < 1.
Thus, by (23), (26), and (27), we have
|βˆµα − β| ≤ |E1|+ |E2|
≤ σ
2
ηc
∗‖γˆ‖2‖α− µα‖2
τ2(1− c∗)DˆT Dˆ +
c∗‖γˆ‖2‖ZTP⊥Dˆ ηˆ‖2
(1− c∗)DˆT Dˆ + |
DˆT ηˆ
DˆT Dˆ
|.
A.2 Proof of Lemma 3.3
Proof. The matrices A and B satisfy that
AB−1 = I − 1
n
(ZTP⊥
Dˆ
Z +
σ2η
τ2
IJ×J)B−1,
where 1n(Z
TP⊥
Dˆ
Z+
σ2η
τ2
IJ×J) andB are both positive definite matrices for 0 < σ2η/τ2 <∞. Thus,
Λmax(AB
−1) = 1− Λmin( 1
n
(ZTP⊥
Dˆ
Z +
σ2η
τ2
IJ×J)B−1) < 1.
One the other hand, matrix A is a rank-1 semi-definite matrix and
Λmax(A) = Trace(A)
=
1
n
DˆTZTZDˆ
DˆT Dˆ
> 0,
if ‖Dˆ‖2 > 0 and Λmin(ZTZ/n) > 0.
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Let uA be such that uA = argmax‖u‖2=1 u
TAu. By the well-known variational theorem, we
have
Λmax(AB
−1) = Λmax(B−1/2AB−1/2)
= max
‖u‖2=1
uTB−1/2AB−1/2u
≥ uTAAuA/uTABuA
≥ Λmax(A)Λ−1max(B),
where the third step is by taking u = B1/2uA/(uTABuA)
1/2 and uTABuA > 0 due toB is a positive
definite matrix.
A.3 Proof of Corollary 3.5
Proof. The proof follows the line of the proof of Theorem 3.2 and is omitted here.
B Implementation details
B.1 Single Gaussian prior
In this section, we discuss the estimation procedure under the hierarchical model (9) - (12).
Start with initial values (βˆ(0), µˆ(0)α ).
E-step: At round t, generate (α(t)i , (τ
2)
(t)
i , (σ
2
η)
(t)
i ), i = 1 . . . ,m, from p(α, τ
2, σ2η|D, βˆ(t−1), µˆ(t−1)α )
by the Gibbs sampling procedure:
α
(t)
i ∼ p(α|D, βˆ(t−1), µˆ(t−1)α , (σ2η)(t)i−1, (τ2)(t)i−1) (28)
(τ2)
(t)
i ∼ p(τ2|D, βˆ(t−1), µˆ(t−1)α , α(t)i , (σ2η)(t)i−1) (29)
(σ2η)
(t)
i ∼ p(σ2η|D, βˆ(t−1), µˆ(t−1)α , α(t)i , (τ2)(t)i−1). (30)
Specifically, the sampling distributions in (28) -(30) are
α
(t)
i ∼ N(θα,Σα)
(τ−2)(t)i ∼ Gamma(ν1 +
J
2
, ν2 +
∑J
j=1(α
(t)
i,j − µˆ(t−1)α )2
2
)
(σ−2η )
(t)
i ∼ Gamma(ν3 +
n
2
, ν4 +
1
2
‖Y − Dˆβˆ(t−1) − Zα(t)i ‖22),
where Σα =
(
ZTZ/(σ2η)
(t)
i−1 + (Γ
(t)
i−1)
−1
)−1
and θα = Σα(Z
T (Y−Dˆβˆ(t−1))/(σ2η)(t)i−1+(Γ(t)i−1)−1µˆ(t−1)α )
for (Γ(t)i−1) = (τ
2)
(t)
i−1IJ×J .
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M-step: Compute
(βˆ(t), µˆ(t)α ) = argmax
(β,µα)∈R2
1
m
m∑
i=1
log p(β, µα|D, α(t)i , (τ2)(t)i , (σ2η)(t)i ).
The maximizers take the form
βˆ(t) =
1
m
m∑
i=1
DˆT (Y − Zαˆ(t)i )
DˆT Dˆ
µˆ(t)α =
∑m
i=1
∑J
j=1 αˆ
(t)
i,j/(τ
2)
(t)
i∑m
i=1 J/(τ
2)
(t)
i
.
Iteratively operate the E-step and M-step until it converges. At the convergence of (βˆ(t), µˆ(t)α ),
produce βˆ(t) as the final estimate of β.
B.2 Mixture Gaussian prior
In this section, we discuss the estimation of MR-EB estimator under prior (11), (12), (14), and (15).
We can still apply the MCEM algorithm with some modifications.
Start with initial values (βˆ(0), µˆ(0)α , pˆ
(0)
0 ).
E-step: Generate (α(t)i , ξ
(t)
i , (σ
2
η)
(t)
i , τ
(t)
i ), i = 1 . . . ,m, from p(α, ξ, σ
2
η, τ
2|D, βˆ(t−1), µˆ(t−1)α , pˆ(t−1)0 )
by Gibbs sampling procedure:
α
(t)
i ∼ N(θα,ξ,Σα,ξ)
ξ
(t)
i,j ∼ Ber(pj), j = 1, . . . , p
(τ−2)(t)i ∼ Gamma(ν1 +
J
2
, ν2 +
1
2
J∑
j=1
(α
(t)
i,j − µˆ(t−1)α ξ(t)i,j )2
(1− ν0)ξ(t)i,j + ν0
)
(σ−2η )
(t)
i ∼ Gamma(ν3 +
n
2
, ν4 +
1
2
‖Y − Dˆβˆ(t−1) − Zα(t)i ‖22),
where Σα,ξ =
(
ZTZ/(σ2η)
(t)
i−1 + (Γ
(t)
ξ,i−1)
−1
)−1
, θα,ξ = Σα,ξ(Z
T (Y − Dˆβˆ(t−1))/(σ2η)(t)i−1 +
(Γ
(t)
ξ,i−1)
−1µˆ(t−1)α ), and pj =
pˆ
(t−1)
0 φ(αˆ
(t)
i,j |µˆ(t−1)α ,(τ2)(t)i−1)
pˆ
(t−1)
0 φ(αˆ
(t)
i,j |µˆ(t−1)α ,(τ2)(t)i−1)+(1−pˆ(t−1)0 )φ(αˆ(t)i,j |0,ν0(τ2)(t)i−1)
for a diagonal
matrix Γ(t)ξ,i−1 with (Γ
(t)
ξ,i−1)j,j = (ν0 + (1− ν0)ξ(t)i−1)(τ2)(t)i−1.
M-step:
(βˆ(t), µˆ(t)α , pˆ
(t)
0 ) = argmax
(β,µα,p0)
1
m
m∑
i=1
log p(β, µα, p0|D, α(t)i , ξ(t)i , (τ2)(t)i , (σ2η)(t)i ).
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The maximizers in the M-step take the form
βˆ(t) =
1
m
m∑
i=1
DˆT (Y − Zαˆ(t)i )
DˆT Dˆ
µˆ(t)α =
∑m
i=1
∑J
j=1 αˆ
(t)
i,j ξˆ
(t)
i,j /(τ
2)
(t)
i∑m
i=1
∑J
j=1 ξˆ
(t)
i,j /(τ
2)
(t)
i
pˆ
(t)
0 =
1
mJ
m∑
i=1
J∑
j=1
ξˆ
(t)
i,j .
At the convergence of (βˆ(t), µˆ(t)α , pˆ(t)), produce βˆ(t) as the final estimate of β.
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